Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...

Unrepresentative pre-clinical models contribute to poor translation of glioblastoma research. We present an ...